Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blood test may predict rheumatoid arthritis:

This article was originally published in Clinica

Executive Summary

A blood test may predict the likelihood that at-risk patients will go on to develop arthritis, report Dutch researchers. A team at Leiden University Medical Centre tested 936 patients with undifferentiated arthritis for the presence of antibodies to cyclic citrullinated peptides (CCP). Three years later 93% of the patients who tested positive for CCP had developed rheumatoid arthritis. Speaking at the American College of Rheumatology Annual Scientific meeting in Orlando, Florida, this month, lead researcher Dr Floris van Gaalen said the team was currently investigating whether using this information to treat patients earlier could help prevent the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel